Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies.Headache. 2018; 58: 496-505
- Determinants of suboptimal migraine diagnosis and treatment in the primary care setting.J Clin Outcomes Manage. 2017; 24: 319-324
- Migraine prevalence, disease burden, and the need for preventive therapy.Neurology. 2007; 68: 343-349
- The international classification of headache disorders, 3rd edition (beta version).Cephalalgia. 2013; 33: 629-808
- Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options.Clin Med (Lond). 2015; 15: 344-350
- The American Headache Society position statement on integrating new migraine treatments into clinical practice.Headache. 2019; 59: 1-18
- Acetylsalicylic acid effervescent 1000 mg (Aspirin) in acute migraine attacks; a multicentre, randomised, double-blind, single-dose, placebo-controlled parallel group study.Cephalalgia. 2000; 20: 663-667
- Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks.Cephalalgia. 2004; 24: 947-954
- Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms.Eur Neurol. 2004; 52: 50-56
- Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin.Neth Heart J. 2014; 22: 107-112
- A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group.Eur Neurol. 1992; 32: 177-184
- Aspirin with or without an antiemetic for acute migraine headaches in adults.Cochrane Database Syst Rev. 2013; CD008041
Food and Drug Administration. FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs [press release]. Available at:http://www.fda.gov/bbs/topics/NEWS/2009/NEW01963.html. Accessed October 8, 2019.
- Cardiovascular risks of non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors: necessary but not sufficient for clinical decision making.Expert Rev Cardiovasc Ther. 2014; 12: 291-293
- Tolerability of the triptans: clinical implications.Drug Saf. 2003; 26: 93-107
- A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group phase III study.Cephalalgia. 2001; 21: 120-128
- Topiramate for the prophylaxis of episodic migraine in adults.Cochrane Database Syst Rev. 2013; CD010610
- Botulinum toxins for the prevention of migraine in adults.Cochrane Database Syst Rev. 2018; 6CD011616
- US approves first monoclonal antibody to prevent migraines.BMJ. 2018; 361: k2228
- Monoclonal antibodies for migraine: an update.J Neurol. 2018; : 1491-1492
- Preliminary report: findings from the aspirin component of the ongoing Physicians’ Health Study.N Engl J Med. 1988; 318: 262-264
- Final report on the aspirin component of the ongoing Physicians’ Health Study.N Engl J Med. 1989; 321: 129-135
- A randomised trial of of prophylactic daily aspirin in British male doctors.Br Med J (Clin Res Ed). 1988; 296: 313-316
- Low-dose aspirin for migraine prophylaxis.JAMA. 1990; 264: 1711-1713.
- A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.N Engl J Med. 2005; 352: 1293-1304
- Migraine and cardiovascular disease: systematic review and meta-analysis.BMJ. 2009; 339: b3914https://doi.org/10.1136/bmj.b3914
- Migraine and subsequent risk of stroke in the Physicians’ Health Study.Arch Neurol. 1995; 52: 129-134
- Low-dose aspirin for migraine prophlaxis in women.Cephalalgia. 2001; 21: 175-183
- The effectiveness of aspirin for migraine prophylaxis: a systematic review.Sao Paulo Med J. 2017; 135: 42-49
Conflict of Interest: PBG discloses that he or his employer Thorek Memorial Hospital receives honoraria for his role as a member of adjudication committees for Allergan, AstraZeneca, Bristol-Myers Squibb-Sanofi, Allergan, TEVA, and Union Chimique Belge; steering committees for the ARRIVE trial funded by Bayer, and another funded by Brainsgate; and data and safety monitoring boards for Amgen, Novartis, and Sanofi. CH discloses that he serves as an independent scientist in an advisory role to investigators and sponsors as chair or member of data and safety monitoring boards for Amgen, British Heart Foundation, Cadila, Canadian Institutes of Health Research, DalCor, Regeneron, and the Wellcome Foundation, to the US Food and Drug Administration, and UpToDate; receives royalties for authorship or editorship of 3 textbooks and as co-inventor on patents for inflammatory markers and cardiovascular disease that are held by Brigham and Women's Hospital; and has an investment management relationship with the West-Bacon Group within SunTrust Investment Services, which has discretionary investment authority and does not own any common or preferred stock in any pharmaceutical or medical device company.
Authorship: All authors had access to the data and a role in writing this manuscript.